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Abstract
Introduction: Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation
against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3)
reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT.
Methods: Adult male and female patients on ERT for at least one year were included. Urinary Gb3 was measured by HPLC,
plasma lysoGb3 by LC-ESI-MS/MS and AB with a neutralization assay.
Results: Of the 59 patients evaluable patients, 0/30 females and 17/29 males developed anti-agalsidase antibodies (AB+).
Only 3/17 males had transient (low) titers (tolerized). All AB+ patients developed antibodies during the first year of
treatment. Change of agalsidase preparation (or dose) did not induce antibody formation. AB+ males had significant less
decline in plasma lysoGb3 compared to AB2 males (p = 0.04). Urinary Gb3 levels decreased markedly in AB2 but remained
comparable to baseline in AB+males (p,0.01). (Lyso)Gb3 reduction in plasma and urine on ERT was correlated with LVmass
reduction in females and development white matter lesions and stroke.
Conclusion: In male patients antibodies against aGal A remained present up to 10 years of ERT. The presence of these
antibodies is associated with a less robust decrease in plasma lysoGb3 and a profound negative effect on urinary Gb3
reduction, which may reflect worse treatment outcome.
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Introduction
The X-linked lysosomal storage disorder Fabry disease is caused
by deficiency of the hydrolase alfa-galactosidase A. Due to this
defect glycosphingolipids, primarily globotriaosylceramide (Gb3,
also known as ceramidetrihexoside) accumulate in various cells of
the body. Gb3 storage is the primary event that ultimately results
in clinical symptoms that start at childhood and comprise
acroparesthesia, anhidrosis, and angiokeratoma. At adult age,
renal, cardiac, and cerebrovascular involvement determine the
reduced life expectancy seen in this disease [1]. Both hemizygous
males and heterozygous females can be affected by Fabry disease,
though in females the disease course is in general milder and more
protracted.
Increased levels of Gb3 can be demonstrated in organs, plasma,
and urine , especially in affected Fabry males. In contrast, the
majority of female Fabry patients have normal Gb3 levels in blood
although most have increased levels of Gb3 in urine [2].
Clinical trials have demonstrated that biweekly infusions
(enzyme replacement therapy or ERT) with two distinct aGal A
preparations reduce the Gb3 content in kidney, heart and skin
[3,4]. Plasma Gb3 levels decline to normal values within 3 months,
while urinary Gb3 clearance is less prominent [3]. Since repeated
organ biopsies are not feasible to evaluate treatment efficacy, serial
measurement of plasma and urine Gb3 as a marker for treatment
efficacy is advised, though the exact relevance for monitoring
therapeutic efficacy of ERT has not been elucidated yet.
Emergence of antibodies towards the infused enzyme is
commonly observed in Fabry males and has a negative impact
on urinary Gb3 clearance [5]. A similar observation was made in
skin, with recurrence of Gb3 accumulation in patients with high
antibody titers [6,7]. To study the clinical impact of these
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antibodies on a biochemical level, renal function was used as
outcome measurement in one study, in combination with clinical
events (e.g. progression of disease) [6]. Analysis of patients who
participated in two clinical trials and for whom long term outcome
of 5 years of ERT was available did not demonstrate a difference
in renal function or clinical events, but this was compared only for
different titer subgroups (high, intermediate, low and no antibod-
ies) and no direct comparison between patients with and without
antibodies was made [6].
The negative effect of antibodies on Gb3 clearance is influenced
by agalsidase dose. Patients who switched from agalsidase alfa or
beta 0,2 mg/kg to agalsidase beta 1,0 mg/kg demonstrated an
additional decrease in plasma Gb3 in AB+ patients 12 months
after switch[8].
Detailed analysis of the effect of long term ERT on plasma Gb3
or urinary Gb3 in relation to the presence agalsidase antibodies is
lacking. Recently de-acylated Gb3 (globotriaosylsphingosine, or
lysoGb3), was shown to be highly increased in plasma of patients
with Fabry disease, its relative elevation exceeding markedly that
of Gb3 [9]. Plasma lysoGb3 proved to be an independent risk
factor for white matter lesions in males and left ventricular
hypertrophy in females [10] and was correlated with other
markers of renal injury [11]. Lifetime exposure to plasma lysoGb3
tended to correlate with disease severity [10]. Enzyme replacement
therapy reduced lysoGb3 levels during the first 12 months and
these reductions were influenced by dose and the presence of
antibodies, with higher doses resulting in a more robust lysoGb3
reduction [12] similar to the effects seen for Gb3 [8]. As lysoGb3
levels in females are more often increased than plasma Gb3 values,
lysoGb3 may be a more attractive biochemical marker than Gb3
for monitoring the effect of ERT.
The aim of the current study was to analyse the impact of
antibodies on long-term biochemical, and clinical outcome of
ERT in Dutch Fabry patients.
Methods
Patients
Of the entire cohort of 70 adult Dutch Fabry patients only those
presenting with classical manifestations of Fabry disease and
treated with either agalsidase alfa or beta (ERT) for at least one
year were included (n= 59). Classical Fabry disease is defined by
the presence of characteristic symptoms and elevated plasma
lysoGb3 and/or Gb3 in hemizygotes, and in case of heterozygotes,
having a mutation known to be associated with a classical
phenotype through literature or a male family member with
classical symptoms [12]. Analyses were conducted until December
2010 or August 2010 in patients with dose-reductions because of a
shortage of agalsidase beta [13]. In all patients plasma lysoGb3,
Gb3 and urinary Gb3 were measured at baseline and for most
patients also in subsequent years. In addition, antibody status was
determined 6 months after start of ERT and yearly after that.
Patients were treated with agalsidase alfa 0.2 mg/kg/2 weeks, with
agalsidase beta 0.2 mg/kg/2 weeks as part of a previous clinical
trial [14] or with agalsidase beta 1.0 mg/kg/2 weeks. Two groups
were analysed: all patients and a subgroup consisting of males
treated for more than five years. The latter group consisted of 8
AB+ and 9 AB2 males.
Clinical evaluations were performed yearly and consisted of
neurological, cardiac, and renal evaluations. The estimated
glomerular filtration rate (eGFR) was calculated according to the
abbreviated MDRD formula [15]. Left Ventricular Mass (LVM)
was assessed by echocardiography and calculated according to
Devereux [16]. Presence of (new) cerebral White Matter Lesions
(WML) was determined with MRI by experienced neuro-
radiologists. A complication was defined as any cardiac compli-
cation, stroke, or end stage renal disease. Cardiac complications
were defined as: onset of atrial fibrillation, onset of any other
rhythm disturbance needing hospitalization, pacemaker, or
implantable cardiac defibrillator (ICD) implantation, cardiac
congestion for which hospital admittance was needed, myocardial
infarction, percutaneous coronary intervention, or coronary artery
bypass graft. ESRD was defined as CKD stage 5 (a GFR,15 ml/
min/1.73 m2), starting dialysis or renal transplantation. The
occurrence of a clinical event was recorded and correlated with
antibody status in patients treated for five years or more. A
summary of the baseline characteristics of the patients included in
the study is given in Table 1.
Consent and IRB approval
Analysis of glycolipids and antibodies is part of standard of care
in the treatment of Fabry disease in our expert center. A waiver
from the hospital’s institutional review board stating was obtained,
stating that this analysis does not apply to the Medical Research
Involving Human Subjects ACT (WMO) and that an official IRB
approval by the institution is not required. All patients gave
written consent for treatment, storage and analysis of blood
samples.
Biochemical analyses
Yearly Gb3, lysoGb3 and antibody assessments were per-
formed. Antibody (AB) analysis was performed by incubating
plasma of patients with 1 ng agalsidase alfa or beta (depending on
the enzyme preparation the patient was treated with). The amount
of plasma needed to neutralize 50% of the enzymatic activity of
1 ng agalsidase alfa or beta was determined by titration. A sample
was considered anti-agalsidase IgG negative if a sample demon-
strated less than 50% neutralization at 5 ml plasma input.
Previously, it was already demonstrated that the amount of
neutralizing activity directly correlates with antibody titer [5]. In
addition, that study also demonstrated that removal of IgG
abolished the inhibitory effect of anti-agalsidase positive plasma.
Globotriaosylceramide (Gb3) and
globotriaosylsphingosine (lyso-Gb3) analysis in plasma
Blood sampling in EDTA was performed for measurement of
Gb3 and lyso-Gb3. Blood samples were centrifuged for 10 minutes
at 3000 rpm to obtain plasma. Plasma was stored at 220uC until
use. Gb3 analysis was performed by using high-performance liquid
chromatography essentially as described by Groener et al [17].
Fifty ml of plasma was used and lipids were extracted according to
Bligh and Dyer [18]. As internal standard C17 sphinganine was
used. The intra-and interassay coefficient of variation is 4% and
14% respectively. Lyso-Gb3 concentrations in plasma samples
were measured using 5,6,7,8,9 13C5-lysoGb3 as internal standard,
extraction by a modification of the method of Bligh and Dyer, and
LC-ESI-MS/MS (Gold et al, submitted). The intra- and interassay
coefficient of variation is 3.5% and 6.3%, respectively.
Gb3 analysis in urine
A 50 mL urine sample was obtained from a 24 hour urine
collection and stored at 220uC until Gb3 analysis was performed
essentially as described for plasma with a slight modification. In
short, 400 ml of urine was used and lipids were extracted according
to Bligh and Dyer [19]. Instead of water, 20 mM phosphate buffer
(pH 8.0) was used in the phase separation.
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Statistical analysis
Results are presented as median (range) or mean6standard
deviation (SD). Chi-square was used for comparison of proportions
and Mann-Whitney U to compare data between two independent
groups and the Kruskal-Wallis test for more than 2 groups.
Spearman’s rho was used for correlation of antibody concentration
(titer) and changes in (lyso)Gb3. For comparison of years of follow-
up to baseline, the Wilcoxon-sign rank test was applied. Repeated
measurements were used for analysis of LVMass and renal
function and Cox regression to analyze time to first white matter
lesions/stroke during ERT and the association with (lyso) Gb3
level.
Results were considered to be statistically significant when p-
values were ,0.05.
Results
Antibody status
Of the 59 adult patients on ERT with one year of follow-up, 29
males and 30 females received at least one year of ERT (table 1).
None of the 30 female patients developed antibodies during
treatment. Of the males, 17 developed antibodies, whereas 12 did
not (table 2). Treatment with agalsidase alfa was associated with a
lower incidence of antibody formation as compared to agalsidase
beta (5/14 on agalsidase alfa vs 12/15 on agalsidase beta,
p = 0.025) but in the agalsidase beta group two different dosages
were used (0.2 and 1,0 mg/kg). Prevalence of antibody formation
between patients treated with 0.2 mg/kg agalsidase alfa or beta
did not differ significantly (5/9 versus 2/5 respectively, p = 0.18).
All patients who developed antibodies did so within the first year
after start of ERT. Treatment alterations after one year of
treatment, i.e. an increase in dose (agalsidase beta 0.2 to 1.0 mg/
kg) or a switch from agalsidase alfa to agalsidase beta, did not
induce antibody formation in those who were negative after one
year of treatment (data not shown).
In three patients AB’s disappeared (i.e. these patients tolerized).
These three patients had their highest titer already within the first
year of treatment, and two of these three had the lowest titer of the
17 AB positive patients. In the other 14 patients, a maximum titer
was achieved at later time points and no tolerization was observed
(non-tolerized AB+ patients).
Plasma lysoGb3 and Gb3
Of the 29 males, 26 males had follow-up plasma Gb3 and
lysoGb3 measurements after one year. In all classic adult male
patients levels of plasma lysoGb3 decreased, but this decrease was
more robust in male patients without antibodies. Baseline lysoGb3
in both groups was not different (p = 0.33). The 3 patients who
tolerized were not included in the subanalysis by AB status; data of
the 12 AB+ male patients were compared to 11 AB2 male
patients. The males in the AB+ group were treated for a median
time of 7.6 (1.3–10.2) years, the AB- group for 6.1 (1.2–8.1) years,
p = 0.24). At baseline, lysoGb3 in both groups was not different
(p = 0.41). In the first year, lysoGb3 decreased in both the AB+
group (from 81 (31–124) to 36 (15–80) nmol/L, n= 12) as well as
in the AB2 group (from 73 (20–103) to 24 (6–47) nmol/L, n= 11).
However during follow-up, lysoGb3 remained elevated (reference
range in healthy controls: 0.3–0.5 nM) and were higher in the
AB+ group compared to the AB2 group (P,0.043, year 1
through 6 compared to baseline, fig 1a). Analysis of plasma Gb3 in
the same patients demonstrated a similar pattern (fig 1b), but
changes were less pronounced as Gb3 levels are less increased at
baseline as compared to lysoGb3. Gb3 levels remained higher in
het AB2 group compared to the AB+ group (p,0.02). Also in
females with follow-up data, both lysoGb3 (from 8 (2.7–24) to 5
(2–13), n = 27) and Gb3 (from 1.6 (0.5–2.8) to 1.1 (0.5–1.8) n= 28)
declined after the first year and remained decreased after 6 years
(p,0.03) (figure 2a and b) (range 2.3–11.4 nM), even though
lysoGb3 did not normalize and remained elevated as compared to
normal controls (0.3–0.5 nM).
Table 1. Baseline characteristics of all adult classic patients treated .1 year.
AB+males AB2males
AB males who
tolerized Females
Number of patients 14 12 3 30
Age at start of ERT (median, range)* 41.0 (18.1–58.5) 22.8 (17.0–65.3) 41.8 (27.2–42.7) 45.6 (15.9–71.5)
LysoGb3 nmol/L (healthy controls 0.3–0.5) 85 (31–124) 74 (20–160) 102 (100–112) 8 (2.7–24)
Plasma Gb3 umol/L (healthy controls 0.45–2.46) 4.2 (1.8–7.1) 3.8 (1.5–5.7) 4.5 (3.1–5.9) 1.5 (0.5–2.8)
Urinary Gb3 nmol/24 h (healthy controls 18–90) 1885 (608–4691) 1928 (250–4494) 1689 (911–2905) 343 (20–2009)
eGFR 84.1 (24.6–130.1) 128.1 (35.5–208.3) 100.8 (38.0–151.1) 98.7 (44.7–180.5)
LVmass (g/m2.7 per year) 53.3 (31.1–77.3) 44.5 (25.4–67.7) 53.6 (29.2–66.4) 44.1 (25.5–120.0)
Presence of white matter lesions 9/12 4/10 2/3 20/28
History of a complication 4/14 1/12 0/3 3/30
*2 males and 4 females started ERT during childhood.
doi:10.1371/journal.pone.0047805.t001
Table 2. Antibody formation in all adult male patients and
the treatment received in the first year *).
Treatment
Agalsidase
alfa
Agalsidase
beta**) Total
Antibodies AB neg 9 3 12
AB pos 5 12 17
Total 14 15 29
*including those who tolerized (n = 3)
**A significant proportion (n = 5) of patients on agalsidase beta received
0,2 mg/kg as part of a clinical trial during the first years of treatment.
doi:10.1371/journal.pone.0047805.t002
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Urinary Gb3
Male patients with antibodies and those without showed a clear
difference in urinary Gb3 reductions. Mean urinary Gb3
decreased from 1818 (250–4494) to 390 (68–735) nmol/24 h
(p = 0.003) in all antibody negative males (n = 11) with follow-up
after the first year and remained decreased after 6 years of ERT
compared to baseline (range 19–387 nmol/24 hours, p = 0.028),
to normal or near normal values, (healthy controls: 18–90 nmol/
24 hours, fig.3a). Mean urinary Gb3 levels in patients with
antibodies in patients treated for 1 year or more with follow-up
(N= 11) did not decrease (from 1812 (608–4691) to 1728 (212–
3619) after 1 year, p= 0.79), and remained elevated for up to 8
years of treatment (216–4547 nmol/24 hours, fig 3a). In the 25
females with urinary Gb3 data, urinary Gb3 decreased from 379
(20–2009) to 173 (17–620) nmol/24 h after the first year and
remained decreased after 6 years of follow-up (28–339 nmol/
24 hours, p = 0.005, fig 3b).
Effect of dose and change of preparation
In the 23 males with follow-up data (excluding the patients who
tolerized), lysoGb3, plasma Gb3 and urinary Gb3 were compa-
rable at baseline, irrespective of preparation or dose received (see
table 3). After the first year of treatment, in males treated with
agalsidase alfa or beta 0.2 mg/kg/2 weeks, the decrease of
lysoGb3 was less pronounced compared to the AB+ group treated
with 1.0 mg/kg/2 weeks (p,0.03) and the AB2 group (p,0.02).
Also the decline of plasma and urinary Gb3 in the AB+ group
treated with agalsidase alfa 0.2 mg/kg/2 weeks was less pro-
nounced compared to the AB+ group treated with 1.0 mg/kg
(p,0.05) and AB2 group (p,0.01).
In males with antibodies and treated with agalsidase beta
1.0 mg/kg/2 weeks, the decrease in lysoGb3 within the initial first
year was comparable to the AB2 group (p = 0.43) as well as the
decrease in plasma Gb3 (p= 0.17) and urinary Gb3 (p = 0.24).
After at least one year of treatment, six AB+ males switched to a
dose of 1.0 mg/kg/2 weeks. In these males, lysoGb3 declined
additionally (median213 nmol/L, range233,29, p = 0.028) one
year after switch. Similarly, following switch plasma Gb3 declined
additionally (median 20.86 (range 21.1, 0 mmol/L, p = 0.028),
while urinary Gb3 declined only in a subset of males (median
2216, range 21072, 576 nmol/24 hours, p = 0.75). Despite this
additional decrease in lysoGb3, plasma and urinary Gb3 levels in
AB+ patients who switched to agalsidase beta 1.0 mg/kg/2 weeks,
these levels remained higher as compared to AB2 patients
(p,0.02).
Correlation with clinical events
To study the relation of antibodies with clinical outcome, males
with antibodies were compared to males without antibodies, the 3
tolerized patients were excluded. AB+ patients were older and had
more advanced disease at start of treatment, as compared to
antibody negative males (see table 1). This hampers the
comparison, as older patients with more advanced disease are
more likely to demonstrate disease progression. Selecting only
those patients treated with at least five years of ERT (8 AB+ and 9
AB2 patients), again males with antibodies were older than the
patients without antibodies. In this subgroup, a tendency towards a
higher incidence of new complications was seen (4/9 in AB+ vs 1/
8 in AB2 patients), but this was not statistically significant
(p = 0.18). No difference was seen in long term outcome of ERT
between these small groups of male patients with regard to renal
function, LVmass and the occurrence of new white matter lesions
on cerebral MRI.
Figure 1. Plasma lysoGb3 and Gb3 in Fabry males. LysoGb3 (A) and plasma Gb3 (B) in 23 classic Fabry males, treated for at least one year (AB+
group n= 12, AB2 group n= 11), depicting mean and 95% confidence intervals.
doi:10.1371/journal.pone.0047805.g001
Figure 2. Plasma lysoGb3 and Gb3 in Fabry females. Plasma lysoGb3 in 27 (A) and Gb3 (B) in 28 Fabry females, treated for at least one year,
depicting mean and 95% CI.
doi:10.1371/journal.pone.0047805.g002
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Clinical relevance of changes in lysoGb3 and Gb3 in
plasma and urine
In females (n = 29), 1 nM lysoGb3 decrease was correlated with
1.5 g/m2.7 decrease in LVmass (p,0.001) independent of age or
years of treatment (see figure 4). For plasma Gb3, 1 mM decrease
of plasma Gb3 was correlated to 6.1 g/m2.7 decrease in LVmass
(p = 0.005), for urinary Gb3 100 nmol/24 h decrease was
associated with 1.3 g/m2.7 decrease in LVmass (p,0.001)
independent of age.
For both males and females, reductions in plasma lysoGb3,
plasma Gb3 and urinary Gb3 within the first year after start of
ERT predicted the hazard of developing white matter lesions and
stroke during ERT, while age and gender did not. The hazard
ratio for developing white matter lesions and stroke was 0.74
(95%: 0.60–0.90) per 10 nM lysoGb3 decrease) during treatment
(p = 0.009, see figure 5)). A reduction of 1 mmol/L plasma Gb3
decreased the hazard ratio to develop white matter lesions or
stroke during follow-up (HR 0.54, 95% CI: 0.34–0.87) (p = 0.012).
Similarly, a decrease of 100 nmol/24 h urinary Gb3 reduced this
hazard ratio to 0.95 (95% CI: 0.92–0.99), p = 0.018. No
correlation between the change of renal function and change of
(lyso) Gb3 could be determined.
Discussion
Here we demonstrate the long term impact of antibody
formation in male Fabry patients treated with ERT on clearance
of urinary Gb3 and to a lesser extent on plasma Gb3 and lysoGb3
levels. In addition, it is also demonstrated that in both AB+ as
AB2 males plasma lysoGb3 levels seem to plateau after an initial
decrease in the first year of treatment and do not reach normal
values. While in those AB+ patients treated with 0.2 mg/kg/2
weeks a switch to a higher dose of 1.0 mg/kg/2 weeks resulted in a
further reduction of lyso(Gb3), these levels still remained higher
compared to AB2 patients. Finally, change of lysoGb3 and
plasma and urinary Gb3 levels correlate with LVMass change in
females, in males with decrease of LVmass and development of
Figure 3. Urinary Gb3 in males and females. A. Urinary Gb3 in classic Fabry males, treated for at least one year (AB+ group n= 11, AB2 group
n= 11). B. Urinary Gb3 in classic Fabry females treated for at least one year (n = 28), depicting mean and 95% confidence interval. The dotted line
denotes upper limit of normal in healthy controls: 18–90 nmol/24 uur.
doi:10.1371/journal.pone.0047805.g003
Table 3. Plasma and urinary lipids in male Fabry patients *.
Total AB+R0.2 AB+F0.2 AB+F1.0 AB2 total
p-value (comparing
all groups)
Number 4 4 4 11
LysoGb3 baseline (nmol/L) 91 (70–119) 79 (31–114) 76 (53–124) 73 0.68
LysoGb3 1 year ERT 65 (38–80) 36 (30–48) 17.5 (15–23) 24 (6–47) 0.003
Plasma Gb3 baseline (umol/L) 4.7 (4.0–7.1) 3.6 (1.8–5.3) 5.3(3.1–6.1) 3.7 (1.5–5.7) 0.14
Plasma Gb3 1 year ERT 3.6 (3.5–4.1) 2.1 (1.5–3.4) 2.0 (1.9–2.1) 1.2 (0.6–1.5) 0.009
Urinary Gb3 baseline
(nmol/24 h)
1786 (1362–2778) 2130 (608–2979) 1790 (669–1812) 1818 (250-4494) 0.81
Urinary Gb3 1 year ERT 2442 (1714–2720) 1748 (1376–3619) 824 (212–1656) 390 (68–735) 0.003
*) including males with follow-up measurements, without the 3 males who tolerized.
doi:10.1371/journal.pone.0047805.t003
Figure 4. LVMass reduction and LysoGb3. LVMass decreases as
lysoGb3 decreases. The dot represents the mean lysoGb3 and mean
LVmass in females at start of ERT treatment, the square depicts mean
lysoGb3 one year after start of ERT.
doi:10.1371/journal.pone.0047805.g004
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strokes or white matter lesions in both males and females. While it
is difficult to predict the consequences of the presence of these
antibodies, a potential negative effect on therapeutic effectiveness
is likely [2,19,20].
Few patients in this study developed complete immune
tolerance towards aGal A during prolonged treatment. This
finding is consistent with a recent report of the postmarketing
surveillance database on agalsidase beta. Of the 571 males treated
with agalsidase beta 73% developed antibodies towards the infused
enzyme, and only 11% of these tolerized, which is similar to our
cohort (3/17, 18%) [21]. The continuous presence of (high) levels
antibodies may also have consequences for future alternative
therapies. It is conceivable that circulating anti-agalsidase
antibodies may exert an effect on future second generation aGal
A enzyme preparations, on treatment with chaperones that aim to
promote the stability of the patient’s endogenous mutated aGal A
or even in gene therapeutic approaches. In other lysosomal storage
disorders, most notably Pompe disease, several strategies have
been proposed to reduce the levels of anti-enzyme antibodies, such
as methotrexate or anti-CD20 [22]. In Fabry disease similar
studies have been done in the mouse-model, but currently no
studies have been performed in man [23]. The findings reported
here strengthen the need to study in more detail the clinical
consequences of antibody formation and approaches on treatment
of patients with antibodies. One such approach may be the use of
higher dosages of agalsidase as a previous study and this report
demonstrate additional reduction of plasma Gb3 and urinary Gb3
following higher dosages[8]. Another possibility may be to develop
immune tolerization regimes.
Previously no correlation between symptoms of Fabry disease
and plasma or urinary Gb3 levels was found [2,19]. which led
some to question its use as a biomarker [19,20]. However, Gb3 is
believed to be pivotal in Fabry pathogenesis and clearance of
accumulated Gb3 in renal capillary endothelium has been
accepted as (surrogate) primary endpoint. In clinical trials
reduction of plasma, urinary or organ Gb3 was considered to
reflect a positive effect of ERT [3,4]. In addition, recent studies
demonstrate that pre-treatment lysoGb3 levels correlated with
some of the clinical features of the disease, such as white matter
lesions in males and overall clinical severity and left ventricular
mass in females [10]. This observation is extended as lysoGb3
response during ERT reflects change in LVmass and development
of white matter lesions. In addition, there is an effect of dose: the
higher dose of agalsidase beta led to more robust biochemical
responses. This is in line with a study in which a lower dose of
agalsidase beta (0.3 mg/kg) led to increases in Gb3 in a subset of
patients [24]. A recent observation of switch to a lower dose as a
result of a worldwide shortage of agalsidase beta again confirms
this finding [13]. These findings once more emphasize that the
debate on dose and treatment outcomes needs to be elucidated
and deserves additional (clinical) studies.
However, even in those patients who do not develop antibodies,
ERT resulted in a far from complete reduction to normal levels of
plasma lysoGb3. After 6 years of treatment, plasma lysoGb3 in
AB2 Fabry patients was on average still 40-fold increased
compared to normal values. The fact that decrease in lysoGb3,
and in plasma and urinary Gb3 correlates with LVmass reduction
upon ERT and influences the hazard of developing white matter
lesions, suggests that a more robust decline of these biomarkers is
probably associated with a more favourable outcome. Both the
phase 4 study with agalsidase beta as well as detailed analyses of
the Dutch cohort demonstrate disease progression in many
patients, suggestive of a very modest effect of ERT in Fabry
disease [14,25,26]. This modest treatment effect as well as the
influence of end organ damage to the responsiveness of the disease
[27,28] may also explain why this study and that of others [6,28]
fail to demonstrate a clear effect of antibodies on treatment
effectiveness. Comparing antibody positive and negative patients
with regard to clinical outcome may also be hampered by the fact
that patients with residual aGal A activity may not only have a
lower risk for developing anti-agalsidase antibodies, but may also
have a less severe course of the disease as compared to those
without residual enzyme activity. The development of anti-
agalsidase antibodies may thus reflect a more severe phenotype
of the disease with faster disease progression.
In this study we made some additional observations that may be
of practical use in the daily care of patients on ERT. None of the
females developed antibodies, which is not surprising as females
have substantial residual enzyme activity (given the X-linked
nature fo the disease) and the infused recombinant human enzyme
is unlikely to be regarded as immunogenic. However, recently
another study reported 12% of treated females developed
antibodies [21]. This observed difference in antibody formation
may be related to the method of antibody detection (neutralization
assay vs ELISA/RIP was used in [21]). Our data suggest, that the
need to monitor antibodies may be of lesser importance in females,
and may be performed less frequently. In addition, in this study all
patients who were antibody negative after one year of treatment
remained so, irrespective of an increase in dose, or change in
enzyme preparation.
Again these observations should be confirmed in larger cohorts,
but may be of importance for physicians considering switching
preparation or increase the dose.
Our study has some limitations. Despite covering the entire
Fabry population of the Netherlands, the total number of analysed
individuals remains limited, especially with regard to those on
longer duration of treatment (.5 years). Moreover, during the
study observation period several patients had their agalsidase dose
and/or preparation changed. Our study demonstrated differences
in antibody formation between the two treatment preparations, at
least when given at their licensed dose. Additional analyses in
larger cohorts are necessary to confirm differences between the
two agalsidase preparations with regard to antibody formation or
effectiveness in reducing Gb3 and lysoGb3. In addition, in this
study we used a neutralizing assay to detect antibodies. While a
previous study demonstrated that all patients with antibodies had
Figure 5. Risk to develop white matter lesions and LysoGb3.
The hazard ratio to develop a (additional) white matter lesion or stroke
decreases as the absolute value of lysoGb3 decreases. The dot
represents mean lysoGb3 for males and females at start of ERT. The
square depicts mean lysoGb3 level one year after start of ERT.
doi:10.1371/journal.pone.0047805.g005
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an aGal A neutralizing effect in vitro[5] it is possible that a patient
may develop antibodies that do not exhibit neutralizing capacity.
The lack of a uniform assay to detect and quantify agalsidase
antibodies hampers direct comparison with other studies. In most
studies on antibody status, antibody analyses was performed by the
manufacturer of the enzyme preparation used. Subsequently,
claims with respect to antibody formation cannot be extrapolated
from one preparation to the other. This emphasizes the need for
standardization of anti agalsidase assays and the results of a
standardization initiative is eagerly awaited [29].
In conclusion, we demonstrated a negative effect of anti-
agalsidase antibodies in male Fabry patients on Gb3 and lysoGb3
levels in plasma and particularly profoundly that of Gb3 in urine.
Change of (lyso)Gb3 is associated with change in certain clinical
parameters, such LVmass and development of white matter lesions
or stroke. Thus, these results suggest a possible deleterious effect
these antibodies on clinical efficacy of ERT, a finding that needs to
be confirmed in a larger cohort. This emphasizes the urgent need
to characterize the impact of anti-agalsidase antibodies on clinical
efficacy of ERT in larger cohorts.
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